NCT Number: NCT04299529
UPRIGHT-HTM will compare risk stratification, treatment efficiency and health economic outcomes of a diagnostic approach based on home blood pressure telemonitoring combined with urinary proteomic profiling with home blood pressure telemonitoring alone
Trial opening soon.
Get Notified55 year–75 year
All sexes
Interventional
Not applicable
European Kidney Health Aliance, Brussels, Belgium
Hypertension is by far the dominant reversible risk factor dwarfing most others in the pathogenesis of chronic kidney disease (CKD) and diastolic left ventricular dysfunction (DVD), two archetypes of chronic age-related diseases, which are rampant in ageing societies in epidemiological transition. Home blood pressure telemonitoring (HTM) is a recommended approach in the diagnosis and management of hypertension. Urinary peptidomic profiling (UPP) holds great promise in individualising prevention and treatment of CKD and DVD and associated complications, such as coronary heart disease. Making use of these modern technologies, UPRIGHT-HTM is an investigator-initiated randomised clinical trial with a patient-centred design, for the first time, comparing HTM combined UPP (experimental group) to HTM alone (control group) in risk profiling and as guide to starting or intensifying management of risk factors to prevent established disease. The trial will run in Europe, sub-Saharan Africa and South America. Eligible patients, aged 55-75 years old, are asymptomatic, but have three or more CKD- or DVD-related risk factors, preferably including hypertension, type 2 diabetes mellitus, or both, and do have internet skills. The primary endpoint consists of a composite of new-onset intermediate endpoints (microalbuminuria, progression of CKD, diabetic or hypertensive retinopathy, electrocardiographic or echocardiographic left ventricular hypertrophy or DVD and hard outcomes (cardiovascular mortality and non-fatal complications, including myocardial infarction, heart failure and stroke). Secondary objectives are demonstrating that combining HTM with UPP is feasible and cost-effective in a multicultural context, defining the molecular signatures of early CKD and DVD, and with help of stakeholders educating and empowering patients. Assuming an accrual time of 1 year, a median follow-up of 4 years, a 10% dropout rate, a 20% risk of the primary endpoint in the control group and 30% risk reduction in the experimental group, requires 1000 patients to be randomised in a 1:1 proportion with the two-sided alpha level and power set 0.05 and 0.80, respectively. The expected outcome is proving the superiority in terms of efficiency and cost-effectiveness of HTM combined with UPP vs HTM alone, which should lead to redesigning the clinical workflow, putting greater emphasis on preventing rather than curing established disease.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Urinary proteomic profiling (UPP) using established multidimensional urinary markers for progression to CKD (CKD273), left ventricular dysfunction (HF1 and HF2) and coronary heart disease (CAD238 and ACSP75) - in-vitro test certified in Germany and by extension in the EU (DE/CA09/0829/IVD/001, DE/CA09/0829/IVD/005).
Time frame: After a run-in period of 2 to 5 weeks to check the eligibility, patients will be randomized and followed up for 4 years
The primary endpoint is a composite of intermediary and "hard" cardiovascular-renal endpoints.
The "intermediate endpoints" are diabetic nephropathy, progression to a higher CKD stage, doubling of serum creatinine, an eGFR decrease by 30% or more or eGFR declining below 45 ml/min/1.73 m2, new-onset hypertensive or diabetic retinopathy, electrocardiographic or echocardiographic left ventricle hypertrophy, and diastolic left ventricular dysfunction.
The "hard" composite cardiovascular endpoint includes cardiovascular mortality, and nonfatal myocardial infarction, nonfatal hospitalised heart failure, and nonfatal stroke, not including transient ischemic attack. The "hard" renal outcomes include macroalbuminuria, the need for renal-replacement therapy, and death to renal causes.
Time frame: After a run-in period of 2 to 5 weeks to check the eligibility, patients will be randomized and followed up for 4 years
The concentration of creatinine in serum, expressed in mg/dl, will be measured, using Jaffe's method with modifications () in certified laboratories applying isotope-dilution mass spectrometry for calibration (Clin Chem 2006; 52: 5-18).
Time frame: After a run-in period of 2 to 5 weeks to check the eligibility, patients will be randomized and followed up for 4 years
eGFR will be derived from the serum creatinine concentration by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (Ann Intern Med 2009; 150: 604-612) and expressed in ml/min/1.73 m2.
Time frame: After a run-in period of 2 to 5 weeks to check the eligibility, patients will be randomized and followed up for 4 years
The National Kidney Foundation Kidney Disease Outcomes Quality Initiative guideline will be followed (Kidney Int Suppl 2013;3:1-150): eGFR ≥90, 60-89, 45-59, 30-44, 15-29 and <15 mL/min/1.73 m2 for Stage 1, 2, 3A, 3B, 4 and 5, respectively
Time frame: After a run-in period of 2 to 5 weeks to check the eligibility, patients will be randomized and followed up for 4 years
Microalbuminuria of 30 microgram per gram creatinine or more in two of three morning urine samples collected on three consecutive days.
Time frame: After a run-in period of 2 to 5 weeks to check the eligibility, patients will be randomized and followed up for 4 years
Non-proliferative diabetic retinopathy (NPDR): early NPDR, at least one microaneurysm ; moderate NDPR, characterized by multiple microaneurysms, dot-and-blot hemorrhages, venous beading, and/or cotton wool spots; severe NPDR, diffuse intraretinal hemorrhages and microaneurysms in four quadrants, venous beading in two or more quadrants, or severe intraretinal microvascular abnormalities
Proliferative diabetic retinopathy (PDR): fibrovascular proliferation extending beyond the internal limiting membrane; vitreous hemorrhage; retinal detachment, macular edema
(https:// https://webeye.ophth.uiowa.edu/eyeforum/tutorials/Diabetic-Retinopathy-Med-Students/Classification.htm)
Time frame: After a run-in period of 2 to 5 weeks to check the eligibility, patients will be randomized and followed up for 4 years
Grade 1: mild narrowing and tortuosity of the retinal arterioles; Grade 2: definite focal retinal arteriolar narrowing and arteriovenous nipping; Grade 3: retinal hemorrhages and cotton wool spots; Grade 4: papilledema
Time frame: After a run-in period of 2 to 5 weeks to check the eligibility, patients will be randomized and followed up for 4 years
The Sokolow-Lyon index is the sum of the S-wave in V1 and the R wave in V5 or V6, whichever is greater; the threshold value is 3.5 mV (PMID 31352838, 19015402, 28789616); in regularly calibrated ECGs, 1 mV is 10 mm along the vertical axis;
The Cornell product is the sum of RaVL and RV5 with 6 mV added for women, multiplied by the QRS duration in milliseconds; the cut-off value is 2440 mV × ms (PMID 31352838, 19015402, 28789616);
Increased R-wave in aVL: the threshold values is 1.1 mV;
ST segment down sloping in V4-V6 with T-top inversion.
Based on these criteria the investigators will classify patients as having or not having electrocariographic LV hypertrophy
Time frame: After a run-in period of 2 to 5 weeks to check the eligibility, patients will be randomized and followed up for 4 years
Guidelines should be applied for acquisition and off-line analysis of the echocardiographic imaging studies (PMID 15452478, 19187853, 27037982); LV mass will be calculated using a formula validated by necropsy (PMID 2936235, 15452478); LVM = 0.8 × (1.04 × (EDD + IVS + LPW)3 - EDD)3) + 0.6; expressed in gram; LV mass will be indexed to body surface; the threshold values are ≥95/≥115 g/m2 in women/men.
Time frame: After a run-in period of 2 to 5 weeks to check the eligibility, patients will be randomized and followed up for 4 years
Diastolic LV dysfunction will be defined as an abnormally low age-specific transmitral E/A ratio, indicative of impaired relaxation, or a mildly-to-moderately elevated left ventricular filling pressure (E/e' >8.5) with normal or decreased age-specific E/A ratio. The ejection fraction should be over 50% (Circ Heart Fail 2009;2: 105-112).
Time frame: After a run-in period of 2 to 5 weeks to check the eligibility, patients will be randomized and followed up for 4 years
ICD10 codes I00-I99
Time frame: After a run-in period of 2 to 5 weeks to check the eligibility, patients will be randomized and followed up for 4 years
ICD10 codes I21,I22
Time frame: After a run-in period of 2 to 5 weeks to check the eligibility, patients will be randomized and followed up for 4 years
ICD10 code I50
Time frame: After a run-in period of 2 to 5 weeks to check the eligibility, patients will be randomized and followed up for 4 years
ICD10 codes I60-I63
Time frame: After a run-in period of 2 to 5 weeks to check the eligibility, patients will be randomized and followed up for 4 years
ICD10 codes N17, N18
Time frame: After a run-in period of 2 to 5 weeks to check the eligibility, patients will be randomized and followed up for 4 years.
Quality of life will be assessed using the EQ-5D quality of life questionnaire (http://www.euroqol.org)
Time frame: After a run-in period of 2 to 5 weeks to check the eligibility, patients will be randomized and followed up for 4 years.
For health-economic evaluation, the EQ-5D patient-administered questionnaire (https://www.euroqol.org) is of particular importance, as Quality Adjusted Life Years (QALYs) can be generated from this simple instrument
Contact information is provided by the study sponsor or research team.
Jan A Staessen, MD, PhD
CONTACT
Zen-Yu Zhang, MD, PhD
CONTACT
KU Leuven
Other
Urinary Proteomics Combined With Home Blood Pressure Telemonitoring for Health Care Reform: a Randomised Controlled Trial
Acronym: UPRIGHT-HTM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04297111
Frailty, Muscle Weakness
Dublin, Ireland
View Trial DetailsNCT02451059
Asthma, Basic Unmet Social Needs
Boston, Massachusetts, United States
View Trial DetailsNCT07443319
Behavior, Health Behavior
View Trial DetailsNCT06002516
Abdominal Pain, Behavior
View Trial Details